Nowell [14] and Wegman [15] reported that SULT1A1*2/*2 carriers had worse outcome in breast cancer patients treated with tamoxifen compared to both homozygous and heterozygous SULT1A1*1 carriers. This evidence concerns the gene SULT1A1 and breast carcinoma.